Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention

  Prostate Cancer

  Free Subscription


21.11.2022

3 BJU Int
4 BMC Cancer
2 BMC Urol
1 Cancer Lett
1 Clin Cancer Res
1 Eur J Radiol
2 Eur Radiol
2 Eur Urol
1 Int J Radiat Oncol Biol Phys
2 Int J Urol
1 J Clin Oncol
1 J Natl Cancer Inst
2 J Nucl Med
5 J Urol
1 Magn Reson Imaging
1 PLoS One
2 Prog Urol
3 Prostate
2 Urology


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BJU Int

  1. KELLY R, Jensen A, Karunaratna N, Wong S, et al
    PSMA PET-CT use prior to systemic therapy in metastatic Castration-Resistant Prostate Cancer (mCRPC).
    BJU Int. 2022 Nov 13. doi: 10.1111/bju.15930.
    PubMed        

  2. DOAN P, Counter W, Papa N, Sheehan-Dare G, et al
    Synchronous versus independent reading of PSMA-PET and MRI to improve diagnosis for prostate cancer.
    BJU Int. 2022 Nov 13. doi: 10.1111/bju.15929.
    PubMed         Abstract available

  3. BRAIDE K, Kindblom J, Thellenberg Karlsson C, Stattin P, et al
    Risk of severe late toxicity after radiotherapy following radical prostatectomy - a nationwide study.
    BJU Int. 2022;130:799-808.
    PubMed         Abstract available


    BMC Cancer

  4. ZENG Z, He W, Jiang Y, Jiang H, et al
    MAPK8IP2 is a potential prognostic biomarker and promote tumor progression in prostate cancer.
    BMC Cancer. 2022;22:1162.
    PubMed         Abstract available

  5. KOPCALIC K, Matic IZ, Besu I, Stankovic V, et al
    Circulating levels of IL-6 and TGF-beta1 in patients with prostate cancer undergoing radiotherapy: associations with acute radiotoxicity and fatigue symptoms.
    BMC Cancer. 2022;22:1167.
    PubMed         Abstract available

  6. HUANG Q, Zi H, Luo L, Li X, et al
    Secular trends of morbidity and mortality of prostate, bladder, and kidney cancers in China, 1990 to 2019 and their predictions to 2030.
    BMC Cancer. 2022;22:1164.
    PubMed         Abstract available

  7. MIYOSHI Y, Kawahara T, Uemura H
    A high serum dehydroepiandrosterone concentration is a predictor of candidates for active surveillance in men with serum prostate-specific antigen < 10 ng/mL.
    BMC Cancer. 2022;22:1169.
    PubMed         Abstract available


    BMC Urol

  8. SUN C, Yang D, Zhu J, Zhou Y, et al
    Modified the 8th AJCC staging system for patients with advanced prostate cancer: a study based on SEER database.
    BMC Urol. 2022;22:185.
    PubMed         Abstract available

  9. CETIN IA, Akay SU, Sengoz M
    Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients.
    BMC Urol. 2022;22:182.
    PubMed         Abstract available


    Cancer Lett

  10. CHUA CW, Kruithof-de Julio M
    Exploring prostate cancer in the post-genomic era.
    Cancer Lett. 2022;553:215992.
    PubMed         Abstract available


    Clin Cancer Res

  11. LIM EA, Bendell JC, Falchook GS, Bauer TM, et al
    Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
    Clin Cancer Res. 2022;28:4871-4884.
    PubMed         Abstract available


    Eur J Radiol

  12. KUROKAWA R, Kato S, Koyama H, Ishida M, et al
    Osteolytic or mixed bone metastasis is not uncommon in patients with high-risk prostate cancer.
    Eur J Radiol. 2022;157:110595.
    PubMed         Abstract available


    Eur Radiol

  13. DENIFFEL D, Perlis N, Ghai S, Girgis S, et al
    Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.
    Eur Radiol. 2022;32:7544-7554.
    PubMed         Abstract available

  14. CORNUD F, Lefevre A, Camparo P, Barat M, et al
    Post-MRI transrectal micro-ultrasonography of transition zone PI-RADS > 2 lesions for biopsy guidance.
    Eur Radiol. 2022;32:7504-7512.
    PubMed         Abstract available


    Eur Urol

  15. HU M, Ye L
    Re: Jihad H. Kaouk, Ethan L. Ferguson, Alp Tuna Beksac, et al. Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique. Eur Urol. 2022;82:551-58.
    Eur Urol. 2022 Nov 7. pii: S0302-2838(22)02779.
    PubMed        

  16. ALBERTSEN PC
    Screening for Prostate Cancer with Prostate-specific Antigen: The Journey Continues.
    Eur Urol. 2022 Nov 10. pii: S0302-2838(22)02772.
    PubMed        


    Int J Radiat Oncol Biol Phys

  17. LIU W, Bauman G
    PSMA PET- and mpMRI-directed Prostate Cancer Salvage.
    Int J Radiat Oncol Biol Phys. 2022;114:1053-1054.
    PubMed        


    Int J Urol

  18. ARAI M, Kosaka T, Yasumizu Y, Takeda T, et al
    Androgen deprivation therapy duration is significantly associated with Testosterone recovery in Japanese patients with prostate cancer.
    Int J Urol. 2022 Nov 14. doi: 10.1111/iju.15098.
    PubMed         Abstract available

  19. TERADA N, Sawada A, Kawanishi H, Fujimoto T, et al
    The efficacy of sequential therapy with docetaxel and cabazitaxel for castration-resistant prostate cancer: A retrospective multi-institutional study in Japan.
    Int J Urol. 2022 Nov 14. doi: 10.1111/iju.15097.
    PubMed         Abstract available


    J Clin Oncol

  20. TRAN PT, Lowe K, Tsai HL, Song DY, et al
    Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.
    J Clin Oncol. 2022 Nov 11:JCO2201662. doi: 10.1200/JCO.22.01662.
    PubMed         Abstract available


    J Natl Cancer Inst


  21. Correction to: RE: Grade Migration of Prostate Cancer in the United States During the Last Decade.
    J Natl Cancer Inst. 2022 Nov 15. pii: 6827851. doi: 10.1093.
    PubMed        


    J Nucl Med

  22. DUAN H, Ghanouni P, Daniel B, Rosenberg J, et al
    A Pilot Study of (68)Ga-PSMA11 and (68)Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer.
    J Nucl Med. 2022 Nov 17. pii: jnumed.122.264448. doi: 10.2967/jnumed.122.264448.
    PubMed         Abstract available

  23. FRAGOSO COSTA P, Pullen L, Kesch C, Krafft U, et al
    F18-PSMA Cerenkov luminescence and flexible autoradiography Imaging in a prostate cancer mouse model and first results of a radical prostatectomy feasibility study in men.
    J Nucl Med. 2022 Nov 10. pii: jnumed.122.264670. doi: 10.2967/jnumed.122.264670.
    PubMed         Abstract available


    J Urol

  24. BOWER PE
    An Algorithm to Personalize Nerve Sparing in Men With Unilateral High-risk Prostate Cancer. Letter.
    J Urol. 2022 Nov 11:101097JU0000000000003054. doi: 10.1097/JU.0000000000003054.
    PubMed        

  25. MARTINI A, Valerio M
    An Algorithm to Personalize Nerve Sparing in Men With Unilateral High-risk Prostate Cancer. Reply.
    J Urol. 2022 Nov 11:101097JU0000000000003055. doi: 10.1097/JU.0000000000003055.
    PubMed        

  26. DAHMANI C, Caron P, Simonyan D, Lacombe L, et al
    Preoperative Circulating 11-Oxygenated Androgens Are Associated With Metastasis-free Survival in Localized Prostate Cancer.
    J Urol. 2022 Nov 14:101097JU0000000000003049. doi: 10.1097/JU.0000000000003049.
    PubMed         Abstract available

  27. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Nov 16:101097JU0000000000003046. doi: 10.1097/JU.0000000000003046.
    PubMed        

  28. PITTMAN A, Moses KA, Washington SL 3rd
    Urologists in Advocacy: The Key to Addressing Disparities in Prostate Cancer.
    J Urol. 2022 Nov 17:101097JU0000000000003000. doi: 10.1097/JU.0000000000003000.
    PubMed        


    Magn Reson Imaging

  29. HU W, Chen L, Lin L, Wang J, et al
    Three-dimensional amide proton transfer-weighted and intravoxel incoherent motion imaging for predicting bone metastasis in patients with prostate cancer: A pilot study.
    Magn Reson Imaging. 2022;96:8-16.
    PubMed         Abstract available


    PLoS One

  30. MENA E, Shih J, Chung JY, Jones J, et al
    Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of 18F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma.
    PLoS One. 2022;17:e0277407.
    PubMed         Abstract available


    Prog Urol

  31. PLOUSSARD G, Fiard G, Barret E, Brureau L, et al
    French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease.
    Prog Urol. 2022;32:1275-1372.
    PubMed         Abstract available

  32. PLOUSSARD G, Roubaud G, Barret E, Beauval JB, et al
    French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance.
    Prog Urol. 2022;32:1373-1419.
    PubMed         Abstract available


    Prostate

  33. TRABZONLU L, Pienta KJ, Trock BJ, De Marzo AM, et al
    Presence of cells in the polyaneuploid cancer cell (PACC) state predicts the risk of recurrence in prostate cancer.
    Prostate. 2022 Nov 13. doi: 10.1002/pros.24459.
    PubMed         Abstract available

  34. ALASKAR A, Abdulraqeb Ali A, Hassan S, Shinwari Z, et al
    Inhibition of signaling downstream of beta-2 adrenoceptor by propranolol in prostate cancer cells.
    Prostate. 2022 Nov 14. doi: 10.1002/pros.24455.
    PubMed         Abstract available

  35. SU CT, Nizialek E, Berchuck JE, Vlachostergios PJ, et al
    Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
    Prostate. 2022 Nov 16. doi: 10.1002/pros.24454.
    PubMed         Abstract available


    Urology

  36. MANN RA, Kasabwala K, Buckley JC, Smith TG, et al
    The "Fragile" Urethra as a Predictor of Early Artificial Urinary Sphincter Erosion.
    Urology. 2022;169:233-236.
    PubMed         Abstract available

  37. SIAPNO AED, Gaither TW, Tandel MD, Kwan L, et al
    Impact of Comprehensive Health Insurance on Quality of Life in Low-Income Hispanic Men with Prostate Cancer.
    Urology. 2022 Nov 15. pii: S0090-4295(22)00954.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: